The device is designed to produce round, accurately sized, centered capsulotomies during the surgical routine through the use of highly focused multi-pulse low-energy discharge along 360 degrees, the Fremont, Calif.-based company said.
“The most compelling patient segment with comorbidities represents 25% of the cataract surgical population and is an ideal target segment to support rapid Zepto penetration to access the early majority. Zepto’s ease of use and superior performance will accelerate broad adoption to become the standard of care with minimal marketing and selling elements,” CEO John Hendrick said in prepared remarks.
The Zepto device and handpiece is an alternative to manual capsulorhexis that allows the capsulotomy alignment with the patient’s visual axis for optimized intraocular lens placement and positioning. The handpiece is connected to a power console positioned away from the sterile field, Mynosys said.